NuCana announced the issuance of a new patent by the United States Patent and Trademark Office, or USPTO, covering NUC-7738’s composition of matter. This patent is expected to serve as a key component of the intellectual property protection for NUC-7738, which currently consists of over 80 issued patents worldwide. NUC-7738 is a novel anti-cancer agent currently in a Phase 2 clinical study in combination with pembrolizumab in PD-1 inhibitor resistant melanoma patients, for which NuCana presented encouraging data at the ESMO Congress 2024 earlier this month.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NCNA:
- Biotech Alert: Searches spiking for these stocks today
- Morning Movers: Bausch + Lomb surges as said to consider potential sale
- NuCana Reports Breakthrough in Resistant Melanoma Treatment
- NuCana presents Data on NUC-7738 in combination with Pembrolizumab
- NuCana price target lowered to $25 from $150 at Oppenheimer